Gilead's Experimental Combo Tablet For HIV Treatment Hits Primary Goal

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.
Business Wire

Gilead Foundation Commits Over $3 Million to Address Food Insecurity

– Commitment Extends Support to Rising Need in California, North Carolina, New Jersey, Maryland, and Washington, D.C. – The funding focuses on reducing barriers to fresh food in vulnerable communities ...
TV Fanatic

Gilead doesn’t use words.

TV Fanatic's owner and Editor-in-Chief has a background in HR and office management. Carissa pivoted careers in 2009 when her love of TV and writing converged. She's written for many TV and ...
SFGate

5 Can't-Miss Quotes From Gilead Sciences Management

Investors are correct to be giddy about Gilead Sciences' second-quarter sales growth and its impact on the company's financials, but second-quarter sales aren't the only things that Gilead Sciences ...
Seeking Alpha

Gilead's New Anti-Obesity Drug: The Real Reason Behind The 25% Stock Surge?

After a disastrous performance in the first half of 2024, Gilead Sciences stock has rebounded strongly since mid-June. With Gilead Sciences due to report its Q2 results on Thursday, it's a good time ...